Drug development

Global Osteoporosis Drugs Market Report (2022 to 2027) - Featuring GlaxoSmithKline, Novartis International and Merck & Co Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 6:00pm
General Health, Health, Pharmaceutical, Physical Therapy, Managed Care, Risk, Calcium, Forecast, Exercise, Fracture, Calcitonin, Investment, Vitamin D, COVID-19, Class, FDA, Research report, Osteoporosis, Bone density, Drug class, Drug development, Therapy, CAGR, Prevalence, Dietary supplement, Pharmaceutical industry, Growth

The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021.

Key Points: 
  • The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021.
  • Remarkably, as there is no cure for osteoporosis, FDA has approved drugs to prevent, slow, or stop osteoporosis progress.
  • Globally, Osteoporosis Drugs Market is primarily driven by a significant rise in the prevalence of osteoporosis disorder.
  • Moreover, the senior population globally possessing high susceptibility for osteoporosis is further presumed to boost the high demand for Osteoporosis Drugs.

Worldwide Digital Biomarkers Industry to 2028 - Early Detection of Neurological Disorders Using Digital Biomarkers Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 1:21pm
Technology, Biotechnology, Health, Data Management, Digital, MHealth, Hospital, Risk, Metabolism, Conditional sentence, Degenerative disease, Region, Incidence, Infection, Diabetes, Quality of life, Chronic pain, Mobile app development, Movement disorders, Mood, COVID-19, Neurodegeneration, Sleep, Biomarker, Technology, Drug development, Science and technology in Asia, Adoption, CAGR, Prevalence, Growth, Video game, Medical imaging, Pharmaceutical industry, Behavior, Female

The global digital biomarkers market report highlights that the market was valued at $1,808.3 million in 2021 and is expected to reach $16,174.0 million by 2028.

Key Points: 
  • The global digital biomarkers market report highlights that the market was valued at $1,808.3 million in 2021 and is expected to reach $16,174.0 million by 2028.
  • As a result, disease diagnosis will become more prevalent, and the global market for digital biomarkers will expand.
  • What technological developments are projected to have the maximum influence on the global digital biomarkers market?
  • What are the key strategies being adopted by market players in the global digital biomarkers market?

Insights on the Shipping Container Global Market to 2027 - by Product, Container Size, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 12:54pm
Other Manufacturing, Manufacturing, Investment, International Organization (journal), Drug development, Adoption, Industry, Automation, Collection, Revolution, Transport, Growth, ISO, COVID-19, Coronavirus, Pharmaceutical industry, Animal, Video game console, Potash

They are used in the transportation and carriage of goods without the requirement of unloading and reloading at intermediate points.

Key Points: 
  • They are used in the transportation and carriage of goods without the requirement of unloading and reloading at intermediate points.
  • How has the global shipping container market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global shipping container market?
  • What is the structure of the global shipping container market and who are the key players?

Patient Centricity, AI-Powered Insights and Diversity in Clinical Trials Among Key Topics at Medidata NEXT London

Retrieved on: 
Wednesday, May 18, 2022 - 9:00am
Other Health, Research, General Health, Pharmaceutical, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, NHS, Senior, Risk, DELMIA, NIHR, Kings Place, CATIA, Patient, Solution, Hearing, List of life sciences, Learning, Professional services, COVID-19, Research, Industry, EMEA, Healthcare industry, SOLIDWORKS, Roche, Euronext Paris, Drug development, SIMULIA, Dassault Group, 3D, Data management, Pharmaceutical industry, Medidata Solutions, Parexel, BIOVIA, GEOVIA, Compass, Lundbeck, Bayer, ENOVIA

NEXT London will include keynote presentations, interactive breakout sessions, patient advocate and customer success stories, product demonstrations and networking opportunities.

Key Points: 
  • NEXT London will include keynote presentations, interactive breakout sessions, patient advocate and customer success stories, product demonstrations and networking opportunities.
  • Attendance to NEXT London and NEXT Basel is free for customers, partners and qualified members of the life sciences community.
  • Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.
  • Dassault Systmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries.

METiS Joins the Roche Accelerator

Retrieved on: 
Wednesday, May 18, 2022 - 12:00pm
Biotechnology, Pharmaceutical, Health, Health, API, AI, Patient, Excipient, Biotechnology, Roche, Drug development, Machine learning, Therapy, Drug discovery, CEO, Fine chemical, Metis

METiS today announced officially joining the Roche Accelerator with the goal to tap into Roches global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai.

Key Points: 
  • METiS today announced officially joining the Roche Accelerator with the goal to tap into Roches global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai.
  • "We are excited to become a member of the Roche Accelerator and to establish a closer connection with a global leader in healthcare like Roche," said Chris Lai, co-founder and CEO of METiS.
  • We look forward to testing METiS proprietary AiTEM platform together and exploring deeper collaboration opportunities to bring optimized therapeutics to patients around the world.
  • Dr. Qiusong Tang, Head of Roche Accelerator, said: We have been witnessing digitalization and AI along the entire pharma R&D value chain, and Im very glad to welcome METiS as the first Roche Accelerator portfolio start-up focusing on AI.

EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395

Retrieved on: 
Wednesday, May 18, 2022 - 12:00pm
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Phases of clinical research, Inflammation, Pharmacology, Patient, ClinicalTrials.gov, Phase, Pharmacokinetics, Reactive airway disease, Epithelium, Principal, University, Safety, Biomarker, Chronic obstructive pulmonary disease, Drug development, Lung, Therapy, Skin, Chronic Respiratory Disease, Pharmaceutical industry, Vaccine, COPD

EpiEndo will begin Phase Ib and Phase IIa studies with EP395 later this year, with top-level data to become available during 2023.

Key Points: 
  • EpiEndo will begin Phase Ib and Phase IIa studies with EP395 later this year, with top-level data to become available during 2023.
  • The Phase Ib study will be a proof of pharmacology study in healthy volunteers.
  • The Phase IIa study will assess the safety and tolerability of EP395 in patients with COPD, as well as assessing biomarkers for anti-inflammatory efficacy.
  • EpiEndos lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.

 Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

Retrieved on: 
Wednesday, May 18, 2022 - 11:30am
Nursing, Biotechnology, Professional Services, Health, Pharmaceutical, Venture Capital, Other Science, Research, Genetics, Science, Clinical Trials, Department, Cancer, GSK, Atlas, Phenotype, Genome, Disease, Population, Wellcome Trust Centre for Gene Regulation and Expression, University, Gene, University of Exeter Medical School, Medical Research Council, Multimedia, Patient, Therapy, Obesity, MRC, Nature, Twin, University College London, Genetics, Cell, Research, Type 2 diabetes, Gurdon Institute, Lists of diseases, King's College London, Statistical genetics, Probability, Life, Center, Human, Publication, Associative group analysis, Drug development, Behavior, Mutation, UK Biobank, Drug discovery, Human genetics, Olaparib, Pharmaceutical industry, Antibiotics, Science, Adrasteia

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.

Key Points: 
  • Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.
  • Studying this genetic diversity in population studies gives us a hypothesis-free, genome wide screen for identifying and validating genes causing or influencing human disease.
  • Combining population genetics with Adrestias synthetic rescue platform provides unprecedented opportunities to efficiently unlock new ways of treating some of the worlds most intractable diseases.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases.

Labcorp Receives Emergency Use Authorization for First Non-Prescription At-Home Collection Kit for Combined COVID-19, Flu and RSV Detection

Retrieved on: 
Wednesday, May 18, 2022 - 11:39am
FDA, Other Health, Other Consumer, Medical Devices, Women, Infectious Diseases, Seniors, Men, Family, Science, Consumer, Other Science, Health, Research, Medical Supplies, Severe acute respiratory syndrome coronavirus 2, Physician, Pixel, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, EUA, FedEx, Multimedia, Patient, Insurance, Vaccine, Influenza, Health, Emergency Use Authorization, COVID-19, FDA, Virus, LH, Hospital, PCR, OnDemand, Drug development, Act, LinkedIn, RSV, Diagnosis, NYSE, Pharmaceutical industry, LabCorp

For those who meet clinical guidelines and have insurance, the kit is available at no upfront cost.

Key Points: 
  • For those who meet clinical guidelines and have insurance, the kit is available at no upfront cost.
  • By using the Labcorp kit to determine whether they have contracted COVID-19, flu or RSV, individuals are choosing the reliability of PCR testingconsidered the gold standard for diagnosing COVID-19 and its variantsto make key health decisions.
  • The Pixel by Labcorp COVID-19+Flu+RSV Test Home Collection Kit is shipped via FedEx Priority Overnight to an individuals home.
  • Test results are available through an individuals Labcorp OnDemand account 1-2 days on average after Labcorp receives the completed collection kit.

Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Tuesday, May 17, 2022 - 9:05pm
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Stony Brook University, Breast, Keck School of Medicine of USC, USC, Medicine, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Breast cancer, EPB, Patient, Woman, Goal, University School, Associate, Syracuse University, Hematology, Cytokine, Clinical trial, Control, COVID-19, Rockefeller University, Annual report, Research, Clinical professor, New York University Grossman School of Medicine, Medical director, Board, Forward-looking statement, University, Safety, Division, Drug development, Therapy, Therapure BioPharma Inc, CMO, Immune system, SEC, NYSE, University of California, San Francisco, CEO, Pharmaceutical industry

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx.

Key Points: 
  • Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx.
  • I look forward to leaning on Janices expertise to further our current research and development efforts in the treatment of oncology.
  • I am impressed with the encouraging data from the ongoing clinical trials of ARX788 and Ambrxs engineered precision biologics technology platform, said Dr. Lu.
  • In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology.

Labcorp to Speak at the UBS 2022 Global Healthcare Conference

Retrieved on: 
Tuesday, May 17, 2022 - 5:01pm
Women, Other Science, Seniors, Research, Diabetes, Men, Family, Consumer, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Cardiology, Biotechnology, AIDS, Health, Science, Patient, UBS, Drug development, Hospital, LinkedIn, Health, Conference, NYSE, LH, Pharmaceutical industry, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 at 2:45 p.m.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 at 2:45 p.m.
  • A live webcast of the fireside chat will be available via the Labcorp Investor Relations website and archived for replay.
  • Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
  • Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp .